PCSK9 Biology and Its Role in Atherothrombosis

Volume: 22, Issue: 11, Pages: 5880 - 5880
Published: May 30, 2021
Abstract
It is now about 20 years since the first case of a gain-of-function mutation involving the as-yet-unknown actor in cholesterol homeostasis, proprotein convertase subtilisin/kexin type 9 (PCSK9), was described. It was soon clear that this protein would have been of huge scientific and clinical value as a therapeutic strategy for dyslipidemia and atherosclerosis-associated cardiovascular disease (CVD) management. Indeed, PCSK9 is a serine protease...
Paper Details
Title
PCSK9 Biology and Its Role in Atherothrombosis
DOI
Published Date
May 30, 2021
Journal
Volume
22
Issue
11
Pages
5880 - 5880
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.